quantitative
Analysis v1
If the price of semaglutide is cut in half, it might become a good value for treating people with heart disease who are overweight or obese—even if they don’t have diabetes—because it could add healthy years of life for less than $50,000 per year of quality life gained.
Evidence from Studies
Supporting (1)
0
Community contributions welcome
0
Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
Computational/Algorithm Study
2025 JanThe study looked at lowering the price of semaglutide by half and found it would likely be a good value for healthcare systems, just like the claim says.
Contradicting (0)
0
Community contributions welcome
No contradicting evidence found
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.